Innovation
In the 2022/2023 business year, we spent EUR 48 million on research and development
Egis launches the first in Russia drug combination treatment for lowering cholesterol levels¹
Hungarian-based Egis Pharmaceuticals PLC launch in Russia the first fixed drug combination of two lipid-lowering agents: rosuvastatin and ezetimibe.
When creative minds meet
One of the pillars of our corporate culture is innovation. We do not only talk about it, but enjusre the flow of ideas with annual forums that offer space for making proposals in connection with scientific research, manufacturing, how to make our administrative process more effective and the latest item on our agenda: digitalization.
Other channels
Egis' products are sold to 100 countries.
Our mission is to serve people with all of our skills, ensuring that they live a long and healthy life
In the 2022/2023 business year, the company’s product portfolio consisted of 653 products
Healthcare and sharing knowledge are in the heart of our CSR activities
Our highlighted past and future events you shouldn't miss
Your browser is out of date. Please, use an updated version!